Literature DB >> 10977131

Constitutive cyclooxygenase-1 and induced cyclooxygenase-2 in isolated human iris inhibited by S(+) flurbiprofen.

N J van Haeringen1, A A van Sorge, V M Carballosa Coré-Bodelier.   

Abstract

The purpose of the present study was to characterize the isoforms of cyclooxygenase (COX) in the human iris before and after stimulation with lipopolysaccharide (LPS) and to determine the selectivity of the nonsteroidal anti-inflammatory drug (NSAID), S(+) flurbiprofen, for inhibition of COX-1 and COX-2 in homogenates of this tissue. Spotblots were made of extracts of human iris in the absence and presence of LPS plus acetylsalicylic acid (aspirin). After reacting with anti-COX-1 and anti-COX-2 immunoglobulin G, the presence of both immunoreactive COX enzymes was substantiated using an indirect immunoperoxidase method. Authentic COX-1 and COX-2 were used as controls. Using an enzyme immune assay (EIA), the production of prostaglandin E2 (PGE2) was quantified in tissue homogenates of human iris under the same conditions as described above. S(+) flurbiprofen was added to tissue homogenates in order to determine the inhibitory effect on PGE2 production. Half maximal inhibitory concentrations (IC50) of S(+) flurbiprofen for the PGE2 production in the tissue homogenates were determined from concentration inhibition curves. The selectivity of S(+) flurbiprofen for inhibition of COX-1 was expressed as the ratio of IC50 for COX-2/COX-1. Spotblots of nonstimulated iris-extracts showed positive staining for COX-1 immunoreactivity (-ir) only. After incubation with LPS plus acetylsalicylic acid, positive staining was observed for both COX-1-ir and COX-2-ir. Concentrations of PGE2 released from homogenates of untreated iris varied from 1.5-4 ng/ml, and of LPS-stimulated tissue from 10-20 ng/ml of assay mixture. S(+) flurbiprofen inhibited PGE2 production of untreated tissue homogenates at an IC50 of 8 x 10(-10) M whereas, in the stimulated tissue, IC50 was found to be 3 x 10(-6) M. The selectivity of S(+) flurbiprofen for inhibition of constitutively present COX-1, relative to the inhibition of induced COX-2, was 3,600. Our results indicate that specific expression of COX isoforms in normal human iris was substantiated at the protein level by immunoreaction on spotblots. COX-1 represents the constitutively present enzyme, and COX-2 appears after stimulation with LPS. At the functional level, S(+) flurbiprofen possesses a specificity for COX-1 in inhibiting PGE2 production.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10977131     DOI: 10.1089/jop.2000.16.353

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  6 in total

1.  Ocular penetration and anti-inflammatory activity of ketorolac 0.45% and bromfenac 0.09% against lipopolysaccharide-induced inflammation.

Authors:  L David Waterbury; Danielle Galindo; Linda Villanueva; Cathy Nguyen; Milan Patel; Lisa Borbridge; Mayssa Attar; Rhett M Schiffman; David A Hollander
Journal:  J Ocul Pharmacol Ther       Date:  2011-02-25       Impact factor: 2.671

2.  Metabolic responses to light in monkey photoreceptors.

Authors:  Shufan Wang; Gülnur Birol; Ewa Budzynski; Robert Flynn; Robert A Linsenmeier
Journal:  Curr Eye Res       Date:  2010-06       Impact factor: 2.424

3.  Role of prostanoid production and receptors in the regulation of retinal endogenous amino acid neurotransmitters by 8-isoprostaglandin E2, ex vivo.

Authors:  Min Zhao; Christopher J Destache; Sunny E Ohia; Catherine A Opere
Journal:  Neurochem Res       Date:  2009-12       Impact factor: 3.996

4.  Uveitic Macular Edema: Treatment Update.

Authors:  Raquel Goldhardt; Bradley Simon Rosen
Journal:  Curr Ophthalmol Rep       Date:  2016-02-18

5.  Energy-dependent endocytosis is responsible for drug transcorneal penetration following the instillation of ophthalmic formulations containing indomethacin nanoparticles.

Authors:  Noriaki Nagai; Fumihiko Ogata; Hiroko Otake; Yosuke Nakazawa; Naohito Kawasaki
Journal:  Int J Nanomedicine       Date:  2019-02-18

Review 6.  Photostability of Topical Agents Applied to the Skin: A Review.

Authors:  Agata Kryczyk-Poprawa; Anna Kwiecień; Włodzimierz Opoka
Journal:  Pharmaceutics       Date:  2019-12-20       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.